Drugs / NKG2D-CAR-NK92 cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05528341 | Jan 2023 → Apr 2026 overdue | refractory malignant neoplasm | Henan Medical University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NKG2D-CAR-NK92 cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05528341 ↗ |
| Modality | Cell therapy | “NKG2D-CAR-NK92 Chimeric Antigen Receptor Modified NK92 Cells” NCT05528341 ↗ |
| Route | Intravenous | “NKG2D-CAR-NK92 cells will be administered intravenously over 1h.” NCT05528341 ↗ |